Patents by Inventor Jer-kang Chen

Jer-kang Chen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Oligonucleotide N3'-P5' phosphoramidates: hybridization and nuclease resistance properties
    Patent number: 5837835
    Abstract: Modified oligonucleotides 3'-NHP(O)(O.sup.-)O-5' phosphoramidates were synthesized on a solid phase support. The phosphoramidate analogs were found to have significantly increased resistance toward phosphodiesterase digestion. Thermal dissociation experiments demonstrated that these compounds form more stable duplexes than phosphodiesters with complementary DNA and particularly RNA strands. Further, the phosphoramidate analogs can also form stable triplexes with double-stranded DNA target, where under similar conditions parent phosphodiester compounds failed to do so.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: November 17, 1998
    Assignee: Lynx Therapeutics, Inc.
    Inventors: Sergei M. Gryaznov, Ronald G. Schultz, Jer-kang Chen
  • Oligodeoxyribonucleotide N3' P5' phosphoramidates
    Patent number: 5726297
    Abstract: Modified oligodeoxyribonucleotide 3'--NHP (O) (O.sup.-) O-5' phosphoramidates were synthesized on a solid phase support. The phosphoramidate analogs were found to have significantly increased resistance toward phosphodiesterase digestion. Thermal dissociation experiments demonstrated that these compounds form more stable duplexes than phosphodiesters with complementary DNA and particularly RNA strands. Further, the phosphoramidate analogs can also form stable triplexes with double-stranded DNA target, where under similar conditions parent phosphodiester compounds failed to do so.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: March 10, 1998
    Assignee: Lynx Therapeutics, Inc.
    Inventors: Sergei M. Gryaznov, Ronald G. Schultz, Jer-Kang Chen
  • Oligonucleotide N3'.fwdarw.P5' phosphoramidates: hybridization and nuclease resistance properties
    Patent number: 5631135
    Abstract: Modified oligonucleotides 3'-NHP(O)(O.sup.-)O-5' phosphoramidates were synthesized on a solid phase support. The phosphoramidate analogs were found to have significantly increased resistance toward phosphodiesterase digestion. Thermal dissociation experiments demonstrated that these compounds form more stable duplexes than phosphodiesters with complementary DNA and particularly RNA strands. Further, the phosphoramidate analogs can also form stable triplexes with double-stranded DNA target, where under similar conditions parent phosphodiester compounds failed to do so.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: May 20, 1997
    Assignee: Lynx Therapeutics, Inc.
    Inventors: Sergei M. Gryaznov, Ronald G. Schultz, Jer-Kang Chen
  • Oligonucleotide N3'-P5' phosphoramidates: hybridization and nuclease resistance properties
    Patent number: 5599922
    Abstract: Modified oligonucleotide 3'-NHP(O)(O.sup.-)O-5' phosphoramidates were synthesized on a solid phase support. The phosphoramidate analogs were found to have significantly increased resistance toward phosphodiesterase digestion. Thermal dissociation experiments demonstrated that these compounds form more stable duplexes than phosphodiesters with complementary DNA and particularly RNA strands. Further, the phosphoramidate analogs can also form stable triplexes with double-stranded DNA target, where under similar conditions parent phosphodiester compounds failed to do so.
    Type: Grant
    Filed: March 18, 1994
    Date of Patent: February 4, 1997
    Assignee: Lynx Therapeutics, Inc.
    Inventors: Sergei M. Gryaznov, Ronald G. Schultz, Jer-kang Chen
  • Oligonucleotide N3.fwdarw.P5' phosphoramidates: triplex DNA formation
    Patent number: 5591607
    Abstract: Modified oligonucleotides 3'-NHP(O)(O.sup.-)O-5' phosphoramidates were synthesized on a solid phase support. The phosphoramidate analogs were found to have significantly increased resistance toward phosphodiesterase digestion. Thermal dissociation experiments demonstrated that these compounds form more stable duplexes than phosphodiesters with complementary DNA and particularly RNA strands. Further, the phosphoramidate analogs can also form stable triplexes with double-stranded DNA target, where under similar conditions parent phosphodiester compounds failed to do so.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: January 7, 1997
    Assignee: Lynx Therapeutics, Inc.
    Inventors: Sergei M. Gryaznov, Ronald G. Schultz, Jer-kang Chen